Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus SODIUM ROSE BENGAL I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus SODIUM ROSE BENGAL I 131.
MPI INDIUM DTPA IN 111 vs SODIUM ROSE BENGAL I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Sodium rose bengal I 131 is a radioactive diagnostic agent that is taken up by hepatocytes and excreted into the bile, allowing imaging of the hepatobiliary system. The radioactive iodine (I-131) emits gamma rays, which can be detected externally to assess liver and gallbladder function.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
5-50 µCi (0.185-1.85 MBq) intravenous bolus for hepatic function imaging. For functional imaging of hepatobiliary system, typical dose: 150-300 µCi (5.55-11.1 MBq) IV.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life is approximately 3-7 days, reflecting slow clearance from the liver and bile.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Primarily hepatic excretion into bile (90-95%), with minimal renal excretion (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical